DOUBLE-BLIND PHASE II STUDY OF MULTIPLE DOSES OF PALIFERMIN (RHUKGF) FOR AIDS

多剂量 Palifermin (RHUKGF) 治疗艾滋病的双盲 II 期研究

• 批准号: 7951580
• 负责人: RONALD T. MITSUYASU
• 金额: $ 4.99万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951580
• 关键词: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dose; Double-Blind Method; Funding; Grant; Institution; Phase II Clinical Trials; Placebos; Research; Research Personnel; Resources; Source; Time; Treatment Protocols; United States National Institutes of Health; keratinocyte growth factor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To demonstrate a greater rise in absolute CD4+ lymphocyte count with one of the three dose regimens of palifermin compared with placebo at the week 12 time point.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 为了证明与安慰剂相比，在12周的时间点，使用三种剂量方案中的一种方案的帕利福明的绝对CD4+淋巴细胞计数有更大的上升。